U.S. markets close in 3 hours 47 minutes
  • S&P 500

    4,059.68
    -20.43 (-0.50%)
     
  • Dow 30

    34,231.33
    -358.44 (-1.04%)
     
  • Nasdaq

    11,423.78
    -44.21 (-0.39%)
     
  • Russell 2000

    1,886.65
    +0.07 (+0.00%)
     
  • Crude Oil

    82.16
    +1.61 (+2.00%)
     
  • Gold

    1,814.70
    +54.80 (+3.11%)
     
  • Silver

    22.81
    +1.02 (+4.70%)
     
  • EUR/USD

    1.0472
    +0.0064 (+0.62%)
     
  • 10-Yr Bond

    3.5670
    -0.1360 (-3.67%)
     
  • GBP/USD

    1.2227
    +0.0165 (+1.37%)
     
  • USD/JPY

    135.7280
    -2.3520 (-1.70%)
     
  • BTC-USD

    16,966.94
    +109.33 (+0.65%)
     
  • CMC Crypto 200

    401.87
    -4.28 (-1.05%)
     
  • FTSE 100

    7,558.49
    -14.56 (-0.19%)
     
  • Nikkei 225

    28,226.08
    +257.09 (+0.92%)
     

Alaunos Therapeutics to Participate in Upcoming Investor Conferences in September

Alaunos Therapeutics, Inc.
Alaunos Therapeutics, Inc.

HOUSTON, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced Kevin S. Boyle Sr., Chief Executive Officer and Drew Deniger, Ph.D., Vice President, Research & Development will be participating in the following upcoming investor conferences.

2022 Wells Fargo Healthcare Conference
Date: Thursday, September 8, 2022
Format: 1x1 Meetings only
Location: Boston, MA

Morgan Stanley 20th Annual Global Healthcare Conference
Date: Monday, September 12, 2022
Format: 1x1 Meetings only
Location: New York, NY

Cantor Oncology, Hematology & HemeOnc Conference
Date: Wednesday, September 28, 2022
Format: Panel Presentation and 1x1 Meetings
Panel: Cell Therapy in Solid Tumors
Location: New York, NY

About Alaunos Therapeutics
Alaunos is a clinical-stage oncology-focused cell therapy company, focused on developing T-cell receptor (TCR) therapies based on its proprietary, non-viral Sleeping Beauty gene transfer technology and its TCR library targeting shared tumor-specific hotspot mutations in key oncogenic genes including KRAS, TP53 and EGFR. The Company has a clinical and strategic collaboration with the National Cancer Institute. For more information, please visit www.alaunos.com.

Investor Relations Contact:
Alex Lobo
Stern Investor Relations
alex.lobo@sternir.com